Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

被引：521

作者：

Ellingson, Benjamin M. ^{[1
,2
,3
,28
,29
,30
,33
,34
]}

Bendszus, Martin ^{[4
,31
]}

Boxerman, Jerrold ^{[5
,30
,34
,35
]}

Barboriak, Daniel ^{[6
,30
,33
,34
]}

Erickson, Bradley J. ^{[7
,32
,33
,34
]}

Smits, Marion ^{[8
,31
]}

Nelson, Sarah J. ^{[9
,29
]}

Gerstner, Elizabeth ^{[10
,28
,32
]}

Alexander, Brian ^{[11
]}

Goldmacher, Gregory ^{[12
,33
]}

Wick, Wolfgang ^{[12
,13
,31
]}

Vogelbaum, Michael ^{[14
,36
]}

Weller, Michael ^{[15
]}

Galanis, Evanthia ^{[16
]}

Kalpathy-Cramer, Jayashree ^{[17
,18
]}

Shankar, Lalitha ^{[19
]}

Jacobs, Paula ^{[19
]}

Pope, Whitney B. ^{[3
,34
]}

Yang, Dewen

Chung, Caroline ^{[20
,21
]}

Knopp, Michael V. ^{[22
,33
]}

Cha, Soonme ^{[9
,24
]}

van den Bent, Martin J. ^{[23
,31
]}

Chang, Susan ^{[24
]}

Al Yung, W. K. ^{[25
]}

Cloughesy, Timothy F. ^{[1
,2
,26
]}

Wen, Patrick Y. ^{[11
,28
]}

Gilbert, Mark R. ^{[27
,36
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Neuro Oncol Program, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Brain Tumor Imaging Lab, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA

[4] Univ Heidelberg Hosp, Dept Neuroradiol, Heidelberg, Germany

[5] Brown Univ, Warrne Alpert Med Sch, Dept Diagnost Imaging, Providence, RI 02912 USA

[6] Duke Univ, Sch Med, Dept Neuroradiol, Durham, NC USA

[7] Mayo Clin, Dept Radiol, Rochester, MN USA

[8] Erasmus MC Univ, Dept Radiol, Rotterdam, Netherlands

[9] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

[10] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA

[11] Harvard Univ, Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA

[12] ICON Med Imaging, Med & Sci Affairs, Warrington, PA USA

[13] Univ Clin Heidelberg, Dept Neurooncol, Natl Ctr Tumor Dis, Heidelberg, Germany

[14] Cleveland Clin, Dept Neurol Surg, Brain Tumor & Neurooncol Ctr, Cleveland, OH 44106 USA

[15] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland

[16] Mayo Clin, Dept Oncol, Div Med Oncol, Rochester, MN USA

[17] Massachusetts Gen Hosp, Boston, MA 02114 USA

[18] Harvard Univ, Sch Med, Boston, MA USA

[19] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA

[20] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada

[21] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[22] Ohio State Univ, Wright Ctr Innovat Biomed Imaging, Div Imaging Sci, Wexner Med Ctr, Columbus, OH 43210 USA

[23] Erasmus MC Canc Inst, Dept Neurooncol, Rotterdam, Netherlands

[24] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA

[25] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Neurooncol, Houston, TX 77030 USA

[26] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA

[27] NCI, Neurooncol Branch, Bethesda, MD USA

[28] ABTC, Baltimore, MD USA

[29] Ivy Consortium Early Phase Clin Trials, Garden City, NY USA

[30] ACRIN, Philadelphia, PA USA

[31] EORTC, Brussels, Belgium

[32] Alliance Clin Trials Oncol, Duarte, CA USA

[33] RSNA Quantitat Imaging Biomarker Alliance QIBA, Arlington, VA USA

[34] Amer Soc Neuroradiol ASNR, Oak Brook, IL USA

[35] Amer Soc Funct Neuroradiol ASFNR, Austin, TX USA

[36] RTOG, Atlanta, GA USA

来源：

NEURO-ONCOLOGY | 2015年 / 17卷 / 09期

关键词：

Brain Tumor Imaging Protocol; clinical trials; glioblastoma; MRI; NEWLY-DIAGNOSED GLIOBLASTOMA; NUCLEAR-MAGNETIC-RESONANCE; RANDOMIZED PHASE-III; MP-RAGE; RESPONSE ASSESSMENT; GRADIENT-ECHO; ADJUVANT TEMOZOLOMIDE; MALIGNANT GLIOMAS; BEVACIZUMAB; CONTRAST;

D O I：

10.1093/neuonc/nov095

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.

引用

页码：1188 / 1198

页数：11

共 66 条

[1]

Akeson P, 1997, ACTA RADIOL, V38, P14

[2]

Akeson P, 1997, ACTA RADIOL, V38, P19

[3] Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations [J].